This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_HEPATOCELLU_CARC_EXALLC for full statistics.
Hepatocellular carcinoma
C3_HEPATOCELLU_CARC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
392423 individuals
Apply sex-specific rule None
392423
Check conditions None
392423
Check pre-conditions, main-only, mode, registry filters
Cause of death: ICD-10
C22.0&
Cancer registry: Topography ICD-O-3
C22
Cancer registry: Morphology ICD-O-3
817[0-5]
Cancer registry: Behaviour codes
3
2 out of 7 registries used, show all original rules.
474
Check minimum number of events None
474
Include endpoints None
474
Remove individuals based on genotype QC
453
C3_HEPATOCELLU_CARC
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
First used in FinnGen datafreeze
DF8
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Hepatocellular carcinoma
based on the number of shared cases.
Broader endpoints:
- Hepatocellular carcinoma (controls excluding all cancers)
- Malignant neoplasm of liver and intrahepatic bile ducts (controls excluding all cancers)
- Malignant neoplasm of liver and intrahepatic bile ducts
- Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder
- Malignant neoplasm of intrahepatic ducts, biliary tract and gallbladder (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 453 | 53 | 400 |
| Unadjusted prevalence (%) | 0.12 | 0.03 | 0.24 |
| Mean age at first event (years) | 71.68 | 71.44 | 71.71 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_HEPATOCELLU_CARC – Hepatocellular carcinoma
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Hepatocellular carcinoma
↥Endpoint not on priority list, no data to show.